These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38700982)

  • 1. Methylation of the chromatin modifier KMT2D by SMYD2 contributes to therapeutic response in hormone-dependent breast cancer.
    Blawski R; Vokshi BH; Guo X; Kittane S; Sallaku M; Chen W; Gjyzari M; Cheung T; Zhang Y; Simpkins C; Zhou W; Kulick A; Zhao P; Wei M; Shivashankar P; Prioleau T; Razavi P; Koche R; Rebecca VW; de Stanchina E; Castel P; Chan HM; Scaltriti M; Cocco E; Ji H; Luo M; Toska E
    Cell Rep; 2024 May; 43(5):114174. PubMed ID: 38700982
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D.
    Toska E; Osmanbeyoglu HU; Castel P; Chan C; Hendrickson RC; Elkabets M; Dickler MN; Scaltriti M; Leslie CS; Armstrong SA; Baselga J
    Science; 2017 Mar; 355(6331):1324-1330. PubMed ID: 28336670
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PI3K Inhibition Activates SGK1 via a Feedback Loop to Promote Chromatin-Based Regulation of ER-Dependent Gene Expression.
    Toska E; Castel P; Chhangawala S; Arruabarrena-Aristorena A; Chan C; Hristidis VC; Cocco E; Sallaku M; Xu G; Park J; Minuesa G; Shifman SG; Socci ND; Koche R; Leslie CS; Scaltriti M; Baselga J
    Cell Rep; 2019 Apr; 27(1):294-306.e5. PubMed ID: 30943409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting MLL Methyltransferases Enhances the Antitumor Effects of PI3K Inhibition in Hormone Receptor-positive Breast Cancer.
    Jones RB; Farhi J; Adams M; Parwani KK; Cooper GW; Zecevic M; Lee RS; Hong AL; Spangle JM
    Cancer Res Commun; 2022 Dec; 2(12):1569-1578. PubMed ID: 36970726
    [TBL] [Abstract][Full Text] [Related]  

  • 5. KMT2C and KMT2D aberrations in breast cancer.
    Tinsley E; Bredin P; Toomey S; Hennessy BT; Furney SJ
    Trends Cancer; 2024 Jun; 10(6):519-530. PubMed ID: 38453563
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of estrogen receptor α by histone methyltransferase SMYD2-mediated protein methylation.
    Zhang X; Tanaka K; Yan J; Li J; Peng D; Jiang Y; Yang Z; Barton MC; Wen H; Shi X
    Proc Natl Acad Sci U S A; 2013 Oct; 110(43):17284-9. PubMed ID: 24101509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KMT2D-mediated H3K4me1 recruits YBX1 to facilitate triple-negative breast cancer progression through epigenetic activation of c-Myc.
    Yao B; Xing M; Zeng X; Zhang M; Zheng Q; Wang Z; Peng B; Qu S; Li L; Jin Y; Li H; Yuan H; Zhao Q; Ma C
    Clin Transl Med; 2024 Jul; 14(7):e1753. PubMed ID: 38967349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regulation of EZH2 by SMYD2-Mediated Lysine Methylation Is Implicated in Tumorigenesis.
    Zeng Y; Qiu R; Yang Y; Gao T; Zheng Y; Huang W; Gao J; Zhang K; Liu R; Wang S; Hou Y; Yu W; Leng S; Feng D; Liu W; Zhang X; Wang Y
    Cell Rep; 2019 Nov; 29(6):1482-1498.e4. PubMed ID: 31693890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2- Metastatic Breast Cancer.
    Mayer IA; Abramson VG; Formisano L; Balko JM; Estrada MV; Sanders ME; Juric D; Solit D; Berger MF; Won HH; Li Y; Cantley LC; Winer E; Arteaga CL
    Clin Cancer Res; 2017 Jan; 23(1):26-34. PubMed ID: 27126994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical modeling of combined phosphatidylinositol-3-kinase inhibition with endocrine therapy for estrogen receptor-positive breast cancer.
    Sanchez CG; Ma CX; Crowder RJ; Guintoli T; Phommaly C; Gao F; Lin L; Ellis MJ
    Breast Cancer Res; 2011 Mar; 13(2):R21. PubMed ID: 21362200
    [TBL] [Abstract][Full Text] [Related]  

  • 11. GREB1 regulates PI3K/Akt signaling to control hormone-sensitive breast cancer proliferation.
    Haines CN; Klingensmith HD; Komara M; Burd CJ
    Carcinogenesis; 2020 Dec; 41(12):1660-1670. PubMed ID: 32894276
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Epigenetic upregulation of MNAT1 by SMYD2 is linked to PI3K/AKT activation and tumorigenesis of pancreatic adenocarcinoma.
    Xu Z; Liu Y; Pan Z; Qin L
    Histol Histopathol; 2024 Feb; 39(2):263-277. PubMed ID: 37232506
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SETDB1 interactions with PELP1 contributes to breast cancer endocrine therapy resistance.
    Liu Z; Liu J; Ebrahimi B; Pratap UP; He Y; Altwegg KA; Tang W; Li X; Lai Z; Chen Y; Shen L; Sareddy GR; Viswanadhapalli S; Tekmal RR; Rao MK; Vadlamudi RK
    Breast Cancer Res; 2022 Apr; 24(1):26. PubMed ID: 35395812
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Preclinical Efficacy of Ron Kinase Inhibitors Alone and in Combination with PI3K Inhibitors for Treatment of sfRon-Expressing Breast Cancer Patient-Derived Xenografts.
    Bieniasz M; Radhakrishnan P; Faham N; De La O JP; Welm AL
    Clin Cancer Res; 2015 Dec; 21(24):5588-600. PubMed ID: 26289070
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dysregulation of AKT Pathway by SMYD2-Mediated Lysine Methylation on PTEN.
    Nakakido M; Deng Z; Suzuki T; Dohmae N; Nakamura Y; Hamamoto R
    Neoplasia; 2015 Apr; 17(4):367-73. PubMed ID: 25925379
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autocrine IGF-I/insulin receptor axis compensates for inhibition of AKT in ER-positive breast cancer cells with resistance to estrogen deprivation.
    Fox EM; Kuba MG; Miller TW; Davies BR; Arteaga CL
    Breast Cancer Res; 2013; 15(4):R55. PubMed ID: 23844554
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhancer Reprogramming Confers Dependence on Glycolysis and IGF Signaling in KMT2D Mutant Melanoma.
    Maitituoheti M; Keung EZ; Tang M; Yan L; Alam H; Han G; Singh AK; Raman AT; Terranova C; Sarkar S; Orouji E; Amin SB; Sharma S; Williams M; Samant NS; Dhamdhere M; Zheng N; Shah T; Shah A; Axelrad JB; Anvar NE; Lin YH; Jiang S; Chang EQ; Ingram DR; Wang WL; Lazar A; Lee MG; Muller F; Wang L; Ying H; Rai K
    Cell Rep; 2020 Oct; 33(3):108293. PubMed ID: 33086062
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Histone-methyltransferase KMT2D deficiency impairs the Fanconi anemia/BRCA pathway upon glycolytic inhibition in squamous cell carcinoma.
    Liu W; Cao H; Wang J; Elmusrati A; Han B; Chen W; Zhou P; Li X; Keysar S; Jimeno A; Wang CY
    Nat Commun; 2024 Aug; 15(1):6755. PubMed ID: 39117659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phosphatidylinositol-3 Kinase Inhibitors, Buparlisib and Alpelisib, Sensitize Estrogen Receptor-positive Breast Cancer Cells to Tamoxifen.
    Chen IC; Hsiao LP; Huang IW; Yu HC; Yeh LC; Lin CH; Wei-Wu Chen T; Cheng AL; Lu YS
    Sci Rep; 2017 Aug; 7(1):9842. PubMed ID: 28852212
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting the PI3K/AKT/mTOR pathway in estrogen receptor-positive breast cancer.
    Ciruelos Gil EM
    Cancer Treat Rev; 2014 Aug; 40(7):862-71. PubMed ID: 24774538
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.